CSIMarket
 



Kura Oncology Inc   (KURA)
Other Ticker:  
 
 



 

What are Kura Oncology Inc's Business Segments?



Kura Oncology Inc is a clinical-stage biopharmaceutical company, which specializes in developing innovative therapies for the treatment of cancer. The company's focus is on discovering and developing precision oncology therapeutics that target specific genetic and biomarker-based super types of cancer. Kura Oncology Inc offers several segments, products, and services.

Segments:

1. Precision Oncology Therapeutics: This segment focuses on developing therapeutic candidates for the treatment of genetically defined cancers.

2. Biomarker-Based Cancer Super Types: This segment is dedicated to studying the biology of cancer super types that share a common genetic signature.

Products:

1. Tipifarnib: Tipifarnib is Kura Oncology's lead product candidate in development for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC). Clinical studies have shown tipifarnib's significant inhibition of HRAS mutant tumors, making it a promising drug for treating this specific type of cancer.

2. KO-947: KO-947 is a potential therapeutic candidate for the treatment of acute myeloid leukemia (AML) and other hematological malignancies. KO-947 is a small molecule that has shown potent in vitro activity against several hematological cancer cells.

Services:

1. Clinical Trial Development: Kura Oncology's clinical trial development team is responsible for designing, managing, and conducting clinical trials of its product candidates.

2. Biomarker Discovery: Kura Oncology's biomarker discovery team focuses on identifying and validating biomarkers that can be used to identify patients who are most likely to benefit from its precision oncology therapeutics.

3. Preclinical Drug Development: Kura Oncology's preclinical drug development team is responsible for identifying and developing new drug candidates that target specific genetic and biomarker-based subtypes of cancer.

In conclusion, Kura Oncology Inc offers precision oncology therapeutics and biomarker-based cancer super types segments, Tipifarnib and KO-947 products, and clinical trial development, biomarker discovery, and preclinical drug development services. These products and services reflect its commitment to developing innovative therapies for the treatment of cancer.
   

Kura Oncology Inc Tax Rate Companies within the Major Pharmaceutical Preparations Industry



To get more information on Kura Oncology Inc's segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com